

## Curriculum vitae et studiorum

Dr. Giacomo Zaccherini, M.D.

### 1. Personal informations

---

Date and place of birth: [REDACTED]  
Personal address: [REDACTED]  
Telephone: [REDACTED]  
Email: [REDACTED] – giacomo.zaccherini@unibo.it  
V.A.T. number: [REDACTED]  
Professional Registry: Ordine dei Medici di Bologna, Italy (n. 16505)

### 2. Academic career

---

July, 2004

**High School Diploma** (Classical Studies) with full marks.

October 10, 2012

**Degree in Medicine and Surgery**, cum laude, at University of Bologna. Degree thesis: "Relation between lifestyle, Metabolic Syndrome, steatosis of the liver and hypertransaminasemia in a population study" (Thesis Advisor: Prof. M. Bernardi)

July 5, 2017

**Specialty Diploma in Internal Medicine**, cum laude, at University of Bologna. Specialty Thesis: "Human Albumin for long-term treatment of patients with liver cirrhosis and ascites" (Thesis Advisor: Prof. P. Caraceni)

2017, September - present

**Research fellow** at University of Bologna (Dpt. of Medical and Surgical Sciences). Investigator of the European clinical study H2020 "Simvastatin and Rifaximin as new therapy for patients with decompensated cirrhosis" (LIVERHOPE Project). Local PI: Prof. Paolo Caraceni.

2018, October - present

**PhD Student** at University of Bologna (Dpt. of Medical and Surgical Sciences). PhD Programme in General Medical and Services Sciences (XXXIV Cycle - Coordinator: Prof. F. Piscaglia).

2019, September – present

**Visiting research fellow** at the European Foundation for the study of Chronic Liver Failure (EF-CLIF), Barcelona, with the grant of a "Marco Polo" scholarship from the Department of Medical and Surgical Sciences of the University of Bologna.

### 3. Clinical activity

---

July, 2012 – July, 2017

**Specialty Training in Internal Medicine** at University of Bologna, with clinical activity at the Unit “Semeiotica Medica” (Chairman: Prof. M. Bernardi; Mentor: Prof. P. Caraceni), composed by the general ward of Internal Medicine and Liver Outpatient/Inpatient Clinic.

September, 2017 - present

**Physician Hepatologist** in Outpatient Clinic for patients with cirrhosis and waitlisted for liver transplantation (Senior Consultant: Prof. P. Caraceni).

S.Orsola-Malpighi University Hospital, Bologna, Italy

### 4. Other professional experiences

---

**ACLS certificate as Experienced Provider** obtained through the Italian Society for Emergency Medicine (SIMEU) according to the American Heart Association (AHA) criteria.

**National Diploma of Clinical Ultrasonography** obtained from the Italian Society of Ultrasonology in Medicine and Biology (SIUMB).

### 5. Academic teaching activities

---

- Teaching assistant and exam committee member in the course “Internal, Aging and Community Medicine” (Degree Programme of Medicine and Surgery).

### 6. Scientific activity

---

#### 6.1 Scientific publications (list attached)

- Printed paper on indexed Journals with impact factor: 30
  - As co-author: 17
  - As workgroup member: 13
- Book chapters: 4
- H-index (source Scopus): 11

ORCID: 0000-0002-3219-6963

Researcher-ID: A-2368-2015

#### 6.2 Editorial board memberships

- Member of the Editorial Board of Annals of Gastroenterology, Hepatology and Endoscopy
- Reviewer for Medical Science Monitor and Gastroenterology Research


### 6.3 Prizes and Grants

- SIMI Award 2018 (Italian Society of Internal Medicine) for the Best Specialty Thesis in Internal Medicine.
- EASL Full bursary (European Association for the Study of the Liver) to attend the 54<sup>th</sup> International Liver Congress, April 2019, Wien, for the poster “Prediction of nosocomial acute-on-chronic liver failure in patients with cirrhosis admitted to hospital with acute decompensation”.
- AIFS Young Investigator Award 2019 (Italian Association for the Study of the Liver) for the poster “Predictors of nosocomial Acute-on-Chronic Liver Failure for the risk stratification of patients with cirrhosis admitted to hospital with Acute Decompensation” (52<sup>nd</sup> AIFS Annual Meeting).
- AIFS Bursaries to attend the 47<sup>th</sup> and the 48<sup>th</sup> Annual Meetings, February 2014 and February 2015, Rome and the 2<sup>nd</sup> Meeting of Young Hepatologists, July 2013, Rome.

### 6.4 Participations to research groups

- Workgroup of national relevance:
  - ANSWER Study group (member of the “Study management group”)
  - REPOSI Study Investigator (SIMI research registry)
- Workgroup of international relevance:
  - CANONIC Study Investigator (EASL-CLIF Consortium)
  - PREDICT Study Investigator (EASL-CLIF Consortium)
  - LIVERHOPE Study Investigator (European Project H2020)
  - CARBALIVE Study Investigator (European Project H2020)

January 30<sup>th</sup>, 2020

Giacomo Zaccherini  


## Peer-reviewed papers published as co-author:

1. Moreau R, Clària J, Aguilar F, Fenaille F, Lozano J, Junot C, Colsch B, Caraceni P, Trebicka J, Pavesi M, Alessandria C, Nevens F, Saliba F, Welzel TM, Albillos A, Gustot T, Fernández J, Moreno C, Baldassarre M, **Zaccherini G**, Piano S, Montagnese S, Vargas V, Genescà J, Solà E, Bernal W, Butin N, Hautbergue T, Cholet S, Castelli F, Jansen C, Steib C, Campion D, Mookerjee R, Rodríguez-Gandía M, Soriano G, Durand F, Benten D, Bañares R, Stauber RE, Gronbaek H, Coenraad MJ, Ginès P, Gerbes A, Jalan R, Bernardi M, Arroyo V, Angeli P; CANONIC Study Investigators of the EASL Clif Consortium, Grifols Chair and the European Foundation for the Study of Chronic Liver Failure (EF Clif). Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. *J Hepatol*. 2019;S0168-8278(19)30696-8.
2. **Zaccherini G**, Baldassarre M, Bartoletti M, Tufoni M, Berardi S, Tamè M, Napoli L, Siniscalchi A, Fabbri A, Marconi L, Antognoli A, Iannone G, Domenicali M, Viale P, Trevisani F, Bernardi M, Caraceni P. Prediction of nosocomial acute-on-chronic liver failure in patients with cirrhosis admitted to hospital with acute decompensation. *JHEP Reports* 2019;4:270-277.
3. Tufoni M, **Zaccherini G**, Caraceni P. Prolonged albumin administration in patients with decompensated cirrhosis: the amount makes the difference. *Ann Transl Med*. 2019;7(Suppl 6):S201.
4. Palmese F, Bolondi I, Giannone FA, **Zaccherini G**, Tufoni M, Baldassarre M, Caraceni P. The Analysis of Food Intake in Patients with Cirrhosis Waiting for Liver Transplantation: A Neglected Step in the Nutritional Assessment. *Nutrients*. 2019;11. pii: E2462.
5. Pose E, Napoleone L, Amin A, Campion D, Jimenez C, Piano S, Roux O, Uschner FE, de Wit K, **Zaccherini G**, Alessandria C, Angeli P, Bernardi M, Beuers U, Caraceni P, Durand F, Mookerjee RP, Trebicka J, Vargas V, Andrade RJ, Carol M, Pich J, Ferrero J, Domenech G, Llopis M, Torres F, Kamath PS, Abraldes JG, Solà E, Ginès P. Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Gastroenterol Hepatol*. 2019. pii: S2468-1253(19)30320-6.
6. **Zaccherini G**, Bernardi M. The role and indications of albumin in advanced liver disease. *Acta Gastroenterol Belg* 2019;82:301-308.
7. Bernardi M, **Zaccherini G**, Caraceni P. Pro: The Role of Albumin in Pre-Liver Transplant Management. *Liver Transpl*. 2019;25:128-134.
8. Bernardi M, **Zaccherini G**. Approach and management of dysnatremias in cirrhosis. *Hepatol Int*. 2018;12:487-499.
9. Tufoni M, Serena Ricci C, **Zaccherini G**. A Case of Immune-Mediated Liver Injury Induced by Olaparib. *Hepatology*. 2018;68:2039-2041.
10. Caraceni P, Riggio O, Angeli P, Alessandria C, Neri S, Foschi FG, Levantesi F, Airoidi A, Boccia S, Svegliati-Baroni G, Fagioli S, Romanelli RG, Cozzolongo R, Di Marco V, Sangiovanni V, Morisco F, Toniutto P, Tortora A, De Marco R, Angelico M, Cacciola I, Elia G, Federico A, Massironi S, Guarisco R, Galioto A, Ballardini G, Rendina M, Nardelli S, Piano S, Elia C, Prestianni L, Cappa FM, Cesarini L, Simone L, Pasquale C, Cavallin M, Andrealli A, Fidone F, Ruggeri M, Roncadori A, Baldassarre M, Tufoni M, **Zaccherini G**, Bernardi M; ANSWER Study Investigators. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. *Lancet*. 2018;391:2417-2429.
11. Bernardi M, Ricci CS, **Zaccherini G**. Role of human albumin in the management of complications of liver cirrhosis. *J Clin Exp Hepatol*. 2014;4:302-11.

12. Bernardi M, Maggioli C, **Zaccherini G**. Human albumin in the management of complications of liver cirrhosis. *Crit Care*. 2012;16:211. doi: 10.1186/cc11218.
13. Giannone FA, Baldassarre M, Domenicali M, **Zaccherini G**, Trevisani F, Bernardi M, Caraceni P. Reversal of liver fibrosis by the antagonism of endocannabinoid CB1 receptor in a rat model of CCl(4)-induced advanced cirrhosis. *Lab Invest*. 2012;92:384-95.
14. Bernardi M, Maggioli C, Dibra V, **Zaccherini G**. QT interval prolongation in liver cirrhosis: innocent bystander or serious threat? *Expert Rev Gastroenterol Hepatol*. 2012;6:57-66.
15. Mirici-Cappa F, Caraceni P, Domenicali M, Gelonesi E, Benazzi B, **Zaccherini G**, Trevisani F, Puggioli C, Bernardi M. How albumin administration for cirrhosis impacts on hospital albumin consumption and expenditure. *World J Gastroenterol*. 2011;17:3479-86.
16. Maggioli C, Santi L, **Zaccherini G**, Bevilacqua V, Giunchi F, Caraceni P. A case of prolonged cholestatic hepatitis induced by azithromycin in a young woman. *Case Reports Hepatol*. 2011;2011:314231.
17. Guaraldi G, Stentarelli C, Zona S, Orlando G, Carli F, Ligabue G, Lattanzi A, **Zaccherini G**, Rossi R, Modena MG, Alexopoulos N, Palella F, Raggi P. Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects. *Atherosclerosis*. 2010;208:222-7.

#### Peer-reviewed papers published as workgroup member:

1. Rossio R, Ardoino I, Franchi C, Nobili A, Mannuccio Mannucci P, Peyvandi F; **REPOSI Investigators**. Patterns of infections in older patients acutely admitted to medical wards: data from the REPOSI register. *Intern Emerg Med*. 2019 Aug 23. doi: 10.1007/s11739-019-02178-1. [Epub ahead of print]
2. Carlotta F, Raffaella R, Ilaria A, Alessandro N, Mannuccio MP; **REPOSI Collaborators**. Prevalence of use and appropriateness of antidepressants prescription in acutely hospitalized elderly patients. *Eur J Intern Med*. 2019 Oct;68:e7-e11. doi: 10.1016/j.ejim.2019.07.025.
3. Pasina L, Brignolo Ottolini B, Cortesi L, Tettamanti M, Franchi C, Marengoni A, Mannucci PM, Nobili A; **REPOSI Investigators**. Need for Deprescribing in Hospital Elderly Patients Discharged with a Limited Life Expectancy: The REPOSI Study. *Med Princ Pract*. 2019;28:501-508.
4. Proietti M, Agosti P, Lonati C, Corrao S, Perticone F, Mannucci PM, Nobili A, Harari S; **REPOSI Investigators**. Hospital Care of Older Patients With COPD: Adherence to International Guidelines for Use of Inhaled Bronchodilators and Corticosteroids. *J Am Med Dir Assoc*. 2019;S1525-8610(19)30159-8.
5. Piano S, Singh V, Caraceni P, Maiwall R, Alessandria C, Fernandez J, Soares EC, Kim DJ, Kim SE, Marino M, Vorobioff J, Barea RCR, Merli M, Elkrief L, Vargas V, Krag A, Singh SP, Lesmana LA, Toledo C, Marciano S, Verhelst X, Wong F, Intagliata N, Rabinowich L, Colombato L, Kim SG, Gerbes A, Durand F, Roblero JP, Bhamidimarri KR, Boyer TD, Maevskaya M, Fassio E, Kim HS, Hwang JS, Gines P, Gadano A, Sarin SK, Angeli P; **International Club of Ascites Global Study Group**. Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. *Gastroenterology*. 2019;156:1368-1380.e10.

6. Mannucci PM, Nobili A, Pasina L; **REPOSI Collaborators** (REPOSI is the acronym of REgistro POLiterapie SIMI, Società Italiana di Medicina Interna). Polypharmacy in older people: lessons from 10 years of experience with the REPOSI register. *Intern Emerg Med*. 2018;13:1191-1200
7. Paciullo F, Proietti M, Bianconi V, Nobili A, Pirro M, Mannucci PM, Lip GYH, Lupattelli G; **REPOSI Investigators**. Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study. *Drugs Aging*. 2018;35:365-373.
8. Bertolotti M, Franchi C, Rocchi MB, Miceli A, Libbra MV, Nobili A, Lancellotti G, Carulli L, Mussi C; **REPOSI Investigators**. Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POLiterapie Società Italiana di Medicina Interna) Study. *Drugs Aging*. 2017;34:311-319.
9. Clària J, Stauber RE, Coenraad MJ, Moreau R, Jalan R, Pavesi M, Amorós À, Titos E, Alcaraz-Quiles J, Oettl K, Morales-Ruiz M, Angeli P, Domenicali M, Alessandria C, Gerbes A, Wendon J, Nevens F, Trebicka J, Laleman W, Saliba F, Welzel TM, Albillos A, Gustot T, Benten D, Durand F, Ginès P, Bernardi M, Arroyo V; **CANONIC Study Investigators of the EASL-CLIF Consortium and the European Foundation for the Study of Chronic Liver Failure (EF-CLIF)**. Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. *Hepatology*. 2016;64:1249-64.
10. Gustot T, Fernandez J, Garcia E, Morando F, Caraceni P, Alessandria C, Laleman W, Trebicka J, Elkrief L, Hopf C, Solís-Munoz P, Saliba F, Zeuzem S, Albillos A, Benten D, Montero-Alvarez JL, Chivas MT, Concepción M, Córdoba J, McCormick A, Stauber R, Vogel W, de Gottardi A, Welzel TM, Domenicali M, Risso A, Wendon J, Deulofeu C, Angeli P, Durand F, Pavesi M, Gerbes A, Jalan R, Moreau R, Ginés P, Bernardi M, Arroyo V; **CANONIC Study Investigators of the EASL-CLIF Consortium**. Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis. *Hepatology*. 2015;62:243-52.
11. Jalan R, Pavesi M, Saliba F, Amorós A, Fernandez J, Holland-Fischer P, Sawhney R, Mookerjee R, Caraceni P, Moreau R, Ginès P, Durand F, Angeli P, Alessandria C, Laleman W, Trebicka J, Samuel D, Zeuzem S, Gustot T, Gerbes AL, Wendon J, Bernardi M, Arroyo V; **CANONIC Study Investigators; EASL-CLIF Consortium**. The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. *J Hepatol*. 2015;62:831-40.
12. Jalan R, Saliba F, Pavesi M, Amorós A, Moreau R, Ginès P, Levesque E, Durand F, Angeli P, Caraceni P, Hopf C, Alessandria C, Rodriguez E, Solis-Muñoz P, Laleman W, Trebicka J, Zeuzem S, Gustot T, Mookerjee R, Elkrief L, Soriano G, Cordoba J, Morando F, Gerbes A, Agarwal B, Samuel D, Bernardi M, Arroyo V; **CANONIC study investigators of the EASL-CLIF Consortium**. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. *J Hepatol*. 2014;61:1038-47.
13. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, Durand F, Gustot T, Saliba F, Domenicali M, Gerbes A, Wendon J, Alessandria C, Laleman W, Zeuzem S, Trebicka J, Bernardi M, Arroyo V; **CANONIC Study Investigators of the EASL-CLIF Consortium**. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. *Gastroenterology*. 2013;144:1426-37, 1437.e1-9.